Ex-HHS work­ers ac­cuse Trump ad­min­is­tra­tion of us­ing flawed da­ta to is­sue fir­ings

Last month
People
Pharma

Sagimet's stock ris­es af­ter Chi­na part­ner re­ports pos­i­tive Phase 3 da­ta in ac­ne

Last month
R&D
China

Anap­tys­Bio de­scribes ‘JAK-like’ ef­fi­ca­cy for PD-1 drug in rheuma­toid arthri­tis

Last month
R&D

Vig­il drug fails a Phase 2; Merus aims to raise $300M

Last month
News Briefing

Strug­gling biotechs suc­cumb to icy mar­ket, as mon­ey dries up and clin­i­cal bets don’t pay off

Last month
People
Pharma

Ex­clu­sive: Cin­Dome gets an­oth­er $40M to ad­vance gas­tro­pare­sis drug

Last month
Financing
Startups

Sion­na se­lects which cys­tic fi­bro­sis drug it will study in a mid-stage test

Last month
R&D

Lil­ly makes a move for long-act­ing in­cretins in tech deal with Swedish biotech

Last month
Deals
R&D

Phar­ma com­pa­nies rush in to buy what they hope will ri­val Keytru­da

Last month
Pharma

Re­mote pa­tient mon­i­tor­ing is ready for its mo­ment

Last month
Health Tech

New CBER chief Prasad promis­es to 'rapid­ly' push even small ad­vances for rare dis­ease drugs

Last month
FDA+

FDA com­mis­sion­er tells Haw­ley he's 'com­mit­ted' to do­ing a mifepri­s­tone re­view

Last month
Pharma
Law

Agenus quick­ly ex­its CD­MO busi­ness by sell­ing as­sets to Zy­dus for $75M up­front

Last month
Deals
Manufacturing

Ve­ra re­draws the terms of up to $500M cred­it fa­cil­i­ty; Tre­vi aims to raise $100M

Last month
News Briefing

Canid rais­es $10M to man­age vac­cines for pe­di­a­tri­cians

Last month
Financing
Startups

BioN­Tech presents im­pres­sive ear­ly da­ta for PD-L1xVEGF in mesothe­lioma

Last month
Deals
R&D

Pyx Health buys Farm­boxRx to reach more Med­ic­aid and Medicare mem­bers

Last month
Deals
Health Tech

Q&A: San­doz CEO Richard Saynor on gener­ic GLP-1s, Trump's in­dus­try im­pact, and Mark Cuban's com­pa­ny

Last month
People
Pharma

At AS­CO, cell ther­a­pies for dead­ly form of brain can­cer make ear­ly strides

Last month
R&D
Cell/Gene Tx

FDA's 2026 bud­get plan seeks to shrink over­all funds, but in­crease user fees

Last month
FDA+

Lyra’s stock soars on Phase 3 suc­cess for chron­ic rhi­nos­i­nusi­tis treat­ment

Last month
R&D

DOGE set to­day as their last day at FDA. In­stead, they're con­tin­u­ing to get full pay and don't work

Last month
People
FDA+

Re­gen­eron makes $80M obe­si­ty deal with Han­soh

Last month
Deals
R&D

Sanofi pays out two STAT6 mile­stones; Ther­a­vance sells more Trel­e­gy roy­al­ties

Last month
News Briefing
First page Previous page 11121314151617 Next page Last page
A service from the Financial Times